TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of “Hold” by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has been given a consensus rating of “Hold” by the thirteen analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $129.5455.

Several equities analysts recently commented on the company. Wall Street Zen lowered TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a report on Tuesday, June 9th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $124.00 price target on shares of TransMedics Group in a research note on Tuesday, June 30th. TD Cowen reiterated a “buy” rating and issued a $120.00 price objective on shares of TransMedics Group in a report on Wednesday, July 1st. Finally, UBS Group began coverage on shares of TransMedics Group in a research report on Tuesday. They issued a “neutral” rating and a $80.00 price objective for the company.

TransMedics Group Stock Up 2.7%

Shares of TransMedics Group stock opened at $76.29 on Wednesday. TransMedics Group has a twelve month low of $60.10 and a twelve month high of $156.00. The stock has a market cap of $2.64 billion, a price-to-earnings ratio of 17.34 and a beta of 1.89. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. The company has a fifty day moving average price of $72.06 and a 200 day moving average price of $101.84.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). The company had revenue of $173.93 million during the quarter, compared to analysts’ expectations of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The company’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same period last year, the business earned $0.70 earnings per share. Equities research analysts forecast that TransMedics Group will post 1.88 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently bought and sold shares of TMDX. Harvest Fund Management Co. Ltd purchased a new position in shares of TransMedics Group during the 3rd quarter valued at approximately $29,000. North Star Investment Management Corp. acquired a new stake in TransMedics Group in the first quarter valued at $30,000. Ascentis Independent Advisors acquired a new stake in TransMedics Group in the first quarter valued at $30,000. Allworth Financial LP boosted its stake in TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the last quarter. Finally, Parallel Advisors LLC grew its holdings in TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after acquiring an additional 83 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.